H
Hassan Gandjini
Researcher at Pfizer
Publications - 8
Citations - 848
Hassan Gandjini is an academic researcher from Pfizer. The author has contributed to research in topics: Tigecycline & Glycylcycline. The author has an hindex of 6, co-authored 8 publications receiving 781 citations.
Papers
More filters
Journal ArticleDOI
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Antonio T. Freire,Vasyl Melnyk,Min Ja Kim,Oleksiy Datsenko,Oleksandr Dzyublik,Felix Glumcher,Yin Ching Chuang,Robert Maroko,Gary Dukart,C. Angel Cooper,Joan M. Korth-Bradley,Nathalie Dartois,Hassan Gandjini +12 more
TL;DR: Overall, the tigecycline regimen was noninferior to the imipenem/cilastatin regimen for the c-mITT but not the CE population; this difference appears to have been driven by results in VAP patients.
Journal ArticleDOI
Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia
Julio A. Ramirez,Nathalie Dartois,Hassan Gandjini,Jean Li Yan,Joan M. Korth-Bradley,Paul C. McGovern +5 more
TL;DR: The hypothesis that a higher area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC ratio) may be necessary to achieve clinical cure in patients with hospital-acquired pneumonia is supported.
Journal ArticleDOI
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study
I. Florescu,M. Beuran,R. Dimov,A. Razbadauskas,M. Bochan,G. Fichev,Gary Dukart,T. Babinchak,C. A. Cooper,Evelyn J. Ellis-Grosse,Nathalie Dartois,Hassan Gandjini +11 more
TL;DR: Tigecycline is safe and effective in hospitalized patients with serious infection caused by MRSA and VRE, and in the ME and m-mITT populations treated with linezolid, there were too few cases of VRE to draw any conclusions.
Journal ArticleDOI
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia
Cristina Tanaseanu,Carlos Bergallo,Osvaldo Teglia,Abel Jasovich,Maria Eugenia Oliva,Gary Dukart,Nathalie Dartois,C. Angel Cooper,Hassan Gandjini,Rajiv Mallick +9 more
TL;DR: Tigecycline appeared safe and achieved cure rates similar to LEV in hospitalized patients with CAP, and microbiologic efficacy and susceptibility to TGC for CAP bacteria were significantly higher in TGC than in LEV.
Journal ArticleDOI
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae
Krasimir Vasilev,Galina Reshedko,Remus Orasan,Miguel Angel Gomez Sanchez,Juri Teras,Tim Babinchak,Gary Dukart,Angel Cooper,Nathalie Dartois,Hassan Gandjini,Russ Orrico,Evelyn Ellis-Grosse +11 more
TL;DR: In this non-comparative study, tigecycline appeared safe and efficacious in patients with difficult-to-treat serious infections caused by resistant Gram-negative organisms.